|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:HLA-B-EIF2AK2 (FusionGDB2 ID:HG3106TG5610) |
Fusion Gene Summary for HLA-B-EIF2AK2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: HLA-B-EIF2AK2 | Fusion gene ID: hg3106tg5610 | Hgene | Tgene | Gene symbol | HLA-B | EIF2AK2 | Gene ID | 3106 | 5610 |
| Gene name | major histocompatibility complex, class I, B | eukaryotic translation initiation factor 2 alpha kinase 2 | |
| Synonyms | AS|B-4901|HLAB | EIF2AK1|PKR|PPP1R83|PRKR | |
| Cytomap | ('HLA-B')('EIF2AK2') 6p21.33 | 2p22.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | major histocompatibility complex, class I, BHLA class I antigen HLA-BHLA class I histocompatibility antigen, B alpha chainMHC HLA-B cell surface glycoproteinMHC HLA-B transmembrane glycoproteinMHC class 1 antigenMHC class I antigen HLA-B alpha chain | interferon-induced, double-stranded RNA-activated protein kinaseP1/eIF-2A protein kinasedouble stranded RNA activated protein kinaseeIF-2A protein kinase 2interferon-inducible elF2alpha kinasep68 kinaseprotein kinase Rprotein kinase, interferon-ind | |
| Modification date | 20200322 | 20200313 | |
| UniProtAcc | . | . | |
| Ensembl transtripts involved in fusion gene | ENST00000412585, ENST00000359635, ENST00000421349, ENST00000425848, ENST00000435618, ENST00000450871, | ||
| Fusion gene scores | * DoF score | 21 X 13 X 8=2184 | 41 X 5 X 15=3075 |
| # samples | 24 | 39 | |
| ** MAII score | log2(24/2184*10)=-3.18586654531133 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(39/3075*10)=-2.97904038136435 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: HLA-B [Title/Abstract] AND EIF2AK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | HLA-B(31321649)-EIF2AK2(37342384), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | HLA-B | GO:0002486 | antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent | 22031944 |
| Hgene | HLA-B | GO:0042270 | protection from natural killer cell mediated cytotoxicity | 2784569|8046333 |
| Tgene | EIF2AK2 | GO:0006468 | protein phosphorylation | 19189853 |
| Tgene | EIF2AK2 | GO:0017148 | negative regulation of translation | 12882984 |
| Tgene | EIF2AK2 | GO:0035455 | response to interferon-alpha | 19840259 |
| Tgene | EIF2AK2 | GO:0046777 | protein autophosphorylation | 22801494 |
| Tgene | EIF2AK2 | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 15121867 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | BLCA | TCGA-GC-A3WC-01A | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
Top |
Fusion Gene ORF analysis for HLA-B-EIF2AK2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000412585 | ENST00000233057 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| 5CDS-intron | ENST00000412585 | ENST00000395127 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| 5CDS-intron | ENST00000412585 | ENST00000405334 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000359635 | ENST00000233057 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000359635 | ENST00000395127 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000359635 | ENST00000405334 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000421349 | ENST00000233057 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000421349 | ENST00000395127 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000421349 | ENST00000405334 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000425848 | ENST00000233057 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000425848 | ENST00000395127 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000425848 | ENST00000405334 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000435618 | ENST00000233057 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000435618 | ENST00000395127 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000435618 | ENST00000405334 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000450871 | ENST00000233057 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000450871 | ENST00000395127 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| intron-intron | ENST00000450871 | ENST00000405334 | HLA-B | chr6 | 31321649 | - | EIF2AK2 | chr2 | 37342384 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for HLA-B-EIF2AK2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for HLA-B-EIF2AK2 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:31321649/:37342384) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | . |
| FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for HLA-B-EIF2AK2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for HLA-B-EIF2AK2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for HLA-B-EIF2AK2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for HLA-B-EIF2AK2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | HLA-B | C0014518 | Toxic Epidermal Necrolysis | 9 | CTD_human |
| Hgene | HLA-B | C0038325 | Stevens-Johnson Syndrome | 9 | CTD_human;ORPHANET |
| Hgene | HLA-B | C1274933 | Drug-Induced Stevens Johnson Syndrome | 9 | CTD_human |
| Hgene | HLA-B | C3658301 | Mycoplasma-Induced Stevens-Johnson Syndrome | 9 | CTD_human |
| Hgene | HLA-B | C3658302 | Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum | 9 | CTD_human |
| Hgene | HLA-B | C0013221 | Drug toxicity | 6 | CTD_human |
| Hgene | HLA-B | C0041755 | Adverse reaction to drug | 6 | CTD_human |
| Hgene | HLA-B | C0013182 | Drug Allergy | 4 | CTD_human |
| Hgene | HLA-B | C0033687 | Proteinuria | 4 | CTD_human |
| Hgene | HLA-B | C0038013 | Ankylosing spondylitis | 3 | CTD_human |
| Hgene | HLA-B | C0004943 | Behcet Syndrome | 2 | CTD_human;ORPHANET |
| Hgene | HLA-B | C0011603 | Dermatitis | 2 | CTD_human |
| Hgene | HLA-B | C0011609 | Drug Eruptions | 2 | CTD_human |
| Hgene | HLA-B | C0026896 | Myasthenia Gravis | 2 | CTD_human |
| Hgene | HLA-B | C0036341 | Schizophrenia | 2 | PSYGENET |
| Hgene | HLA-B | C0039263 | Takayasu Arteritis | 2 | ORPHANET |
| Hgene | HLA-B | C0406537 | Morbilliform Drug Reaction | 2 | CTD_human |
| Hgene | HLA-B | C0751339 | Myasthenia Gravis, Generalized | 2 | CTD_human |
| Hgene | HLA-B | C0751340 | Myasthenia Gravis, Ocular | 2 | CTD_human |
| Hgene | HLA-B | C0011633 | Dermatomyositis | 1 | CTD_human |
| Hgene | HLA-B | C0015230 | Exanthema | 1 | CTD_human |
| Hgene | HLA-B | C0017638 | Glioma | 1 | CTD_human |
| Hgene | HLA-B | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| Hgene | HLA-B | C0019693 | HIV Infections | 1 | CTD_human |
| Hgene | HLA-B | C0020517 | Hypersensitivity | 1 | CTD_human |
| Hgene | HLA-B | C0026654 | Moyamoya Disease | 1 | GENOMICS_ENGLAND |
| Hgene | HLA-B | C0027697 | Nephritis | 1 | CTD_human |
| Hgene | HLA-B | C0033975 | Psychotic Disorders | 1 | PSYGENET |
| Hgene | HLA-B | C0039103 | Synovitis | 1 | CTD_human |
| Hgene | HLA-B | C0221056 | Adult type dermatomyositis | 1 | CTD_human |
| Hgene | HLA-B | C0259783 | mixed gliomas | 1 | CTD_human |
| Hgene | HLA-B | C0263666 | Dermatomyositis, Childhood Type | 1 | CTD_human |
| Hgene | HLA-B | C0410574 | Synovial Hypertrophy | 1 | CTD_human |
| Hgene | HLA-B | C0555198 | Malignant Glioma | 1 | CTD_human |
| Hgene | HLA-B | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| Hgene | HLA-B | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| Hgene | HLA-B | C1527304 | Allergic Reaction | 1 | CTD_human |
| Hgene | HLA-B | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| Hgene | HLA-B | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| Hgene | HLA-B | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
| Hgene | HLA-B | C4505456 | HIV Coinfection | 1 | CTD_human |
| Tgene | C0021400 | Influenza | 1 | CTD_human | |
| Tgene | C0033578 | Prostatic Neoplasms | 1 | CTD_human | |
| Tgene | C0038220 | Status Epilepticus | 1 | CTD_human | |
| Tgene | C0270823 | Petit mal status | 1 | CTD_human | |
| Tgene | C0311335 | Grand Mal Status Epilepticus | 1 | CTD_human | |
| Tgene | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human | |
| Tgene | C0393734 | Complex Partial Status Epilepticus | 1 | CTD_human | |
| Tgene | C0751522 | Status Epilepticus, Subclinical | 1 | CTD_human | |
| Tgene | C0751523 | Non-Convulsive Status Epilepticus | 1 | CTD_human | |
| Tgene | C0751524 | Simple Partial Status Epilepticus | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies